Scaffold for alloprosthetic composite implant

Information

  • Patent Grant
  • 11013602
  • Patent Number
    11,013,602
  • Date Filed
    Wednesday, June 28, 2017
    6 years ago
  • Date Issued
    Tuesday, May 25, 2021
    2 years ago
Abstract
An alloprosthetic composite implant comprising includes a structural porous scaffold having a pore density profile corresponding to a density profile of bone to be replaced. A plurality of cells are seeded within pores of the porous scaffold and grown by incubation. The cells may include osteoblasts and/or stem cells to form the structure of the implant, and one or more cartilage layers may be grown on top of the scaffold. The pore density profile of the scaffold may be formed based on one or both of the bone density profile of the bone to be removed, and the bone density profile of the native bone that will be in contact with the alloprosthetic implant. A robot may be employed reo resect the native bone and also to shape the alloprosthetic implant to fit into place in the native bone.
Description
BACKGROUND OF THE DISCLOSURE

Joint replacement, particularly articulating joint replacement, is a commonly performed procedure in orthopedic surgery. However, the ideal material for replacement joints remains elusive. Typically, joint reconstruction involves repair of a bony defect, articular cartilage and in some cases, other tissue such as one or more joining ligaments. For example, in a typical knee arthroplasty procedure, damaged or otherwise deficient cartilage may be removed from the patient along with a portion of subchondral bone. A prosthetic knee implant is implanted into the knee, typically with a metallic portion providing structural support and a plastic component coupled to the metallic portion to provide a bearing surface for articulation with respect to another implant or native tissue.


The goal of a joint arthroplasty is generally to restore functionality to the joint in a way that closely mimics a healthy native joint. Metal and plastic implant may have a number of benefits, for example, ease and accuracy of production. However, there is increasing interest in designing implants, articular or otherwise, that are at least partially formed of biologic components to more closely mimic the tissue being replaced.


BRIEF SUMMARY

According to a first aspect of the disclosure, an alloprosthetic composite implant for replacing a joint includes a structural porous scaffold having a pore density profile corresponding to a density profile of a bone of the joint to be replaced. A plurality of cells is seeded within pores of the porous scaffold. At least one layer of cartilage may be positioned on an end of the scaffold, the cartilage adapted to replace at least a portion of a joint surface of the joint. The density profile of the porous scaffold may include a relatively low density inner portion adapted to contact native bone of a patient, and a relatively high density outer portion opposite the inner portion. The porous scaffold may be formed from at least one of metal and collagen. The cells seeded within pores of the porous scaffold may be selected from the group consisting of stem cells and osteoblasts. The at least one layer of cartilage may include an outer gliding layer of cartilage and an inner layer of cartilage underneath the outer gliding layer. The pore density of a portion of the scaffold configured to contact a native bone of a patient may be formed to correspond to a bone density of the native bone to be contacted.


According to another aspect of the disclosure, a method of implanting an alloprosthetic composite implant includes forming a scaffold having a pore density profile, seeding a plurality of viable cells into the scaffold, incubating the scaffold including the plurality of viable cells, robotically resecting native bone of a patient, and robotically machining the alloprosthetic composite implant following incubation to have a shape corresponding to the native bone of the patient that is to be replaced. The step of forming the scaffold may be performed by additive manufacturing, such as 3-D printing. The method may also include determining a bone density profile of a bone of a patient to be replaced by the alloprosthetic composite implant. In this case, the pore density profile of the scaffold may be formed based on the determined bone density profile of the bone to be replaced. The method may additionally or alternately include determining a bone density profile of a native bone to be contacted by the alloprosthetic composite implant. In this case, a portion of the scaffold intended to contact the native bone may be formed with a pore density profile based on the determined bone density profile. The step of seeding a plurality of viable cells into the scaffold may include seeding osteoblasts and/or pluripotent cells into the scaffold. A first inner layer of cartilage may be formed on the scaffold, and a second layer of cartilage may be formed on the first layer of cartilage. The step of robotically machining the alloprosthetic composite implant may be performed intraoperatively. The step of incubating the scaffold may include incubating the scaffold in a nutrient rich medium. The step of robotically resecting native bone of the patient may include forming a first interlocking shape in the native bone and the step of robotically machining the alloprosthetic composite implant may include forming a second interlocking shape in the alloprosthetic composite having a complementary shape to the first interlocking shape.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a highly schematic view of the bones of a knee joint.



FIG. 2 is a highly schematic view of the bones of a knee joint during a unicondylar knee replacement.



FIG. 3 is a highly schematic view of a prosthesis implanted into the knee joint of FIG. 2.



FIG. 4A is a perspective view of a scaffold of the prosthesis of FIG. 3.



FIG. 4B is a cross-section of the scaffold of FIG. 4A taken along the lines 4B-4B of FIG. 4A.



FIG. 5 is a perspective view of stem cells being introduced to the scaffold of FIG. 4A.



FIG. 6 is a cross-section of the scaffold of FIG. 4A with bone cells therein.



FIG. 7 is a cross-section of prosthesis of FIG. 3 with layers of cartilage.



FIG. 8A is schematic view of a robotic device resecting a bone.



FIG. 8B is a schematic view of the robotic device of FIG. 8A shaping the prosthetic implant of FIG. 7.





DETAILED DESCRIPTION

Different options are available for designing a prosthetic implant. For example, implants may be formed completely of metals and/or plastics and/or other non-biologic materials. Alternatively, implants may be formed of biologic materials, which may be, for example, autografts, allografts, and/or xenografts. Such biologic implants may be harvested from a donor and implanted as harvested (or as modified following harvesting). However, when using fresh or frozen osteochondral allograft materials, it can be very difficult to get the patient's bone to grow into the surface of the allograft. Biologic implants may also be grown ex vivo. For example, attempts have been made to grow bone and cartilage for later implantation as part of a joint arthroplasty or other joint repair procedure. Other implants may attempt to combine non-biologic implants with biological components. One example of this is metallic implants that have a porous surface to allow the patient's bone to grow into the metallic portion in vivo on a first side of the implant, with a metallic or plastic bearing surface on a second side to provide an articular surface for the prosthetic joint.


The disclosure provided herein is generally directed to an alloprosthetic composite (“APC”) implant, including a scaffold used in the implant. Although the disclosure is directed generally to a specific example of a tibial implant, it should be understood that the concepts provided herein may be applied to other APC implants, which are described in greater detail below. One example of an application of the APC implant described herein is a unicondylar or partial knee replacement. For example, FIG. 1 shows a highly schematic drawing of a knee joint including the distal portion of a femur 10 and the proximal portion of a tibia 20. The distal femur 10 includes a medial femoral condyle which articulates against a medial tibial condyle 22 and a lateral femoral condyle which articulates against a lateral tibial condyle 24. The distal femur 10 does not articulate directly against bone of the tibia 20, but rather against fibrocartilaginous tissue known as menisci that are positioned on top of the proximal tibia 20. Due to age, disease, trauma, or other causes, one or more of the articular surfaces of the tibia 20 may need to be replaced. For example, in a unicondylar knee replace, one of the tibial or femoral condyles may be replaced with a prosthetic implant. Although a unicondylar knee replacement may include replacement of both medial condyles of the femur 10 and tibia 20 (or both lateral condyles), the procedure for simplicity is described as solely replacement of the medial tibial condyle 22.


In such a unicondylar knee replacement, at least a portion of the medial tibial condyle 22, including the cartilage and subchondral bone, is removed, for example with a manually controlled or robotically controlled cutting tool, as shown in FIG. 2. Once the tibia 20 is properly prepared, an implant 100, such an APC implant formed according to the disclosure provided below, may be attached to the bone to restore normal or near-normal function to the joint, as shown in FIG. 3. It should be understood that implant 100 in FIG. 3 is represented as a block merely for ease of illustration, and, as explained in greater detail below, would be shaped to correspond to the particular anatomy of the patient as needed.



FIGS. 4A-B are schematic illustrations of a scaffold 200 for use in creating an APC implant 100. In one example, scaffold 200 may be formed of a metallic material, such as titanium, formed into a porous three-dimensional structure. Preferably, scaffold 200 is formed via additive manufacturing, for example via 3D printing. One benefit of forming scaffold 200 via 3D printing is the ability to precisely control the structure, including the porosity, of the scaffold 200. For example, because part of the goal of using APC implant 100 is to mimic the native anatomy, it would be desirable to have at least a portion of scaffold 200 be filled with bone tissue that mimics the variable structure of the native bone. In particular, within a bone such as tibia 20, a transverse cross-section through tibia 20 would show that the outer cortical rim portions of tibia 20 have greater density compared to the center portions of tibia 20 which is generally referred to as cancellous (or spongy or trabecular) bone. It is possible to design scaffold 200 in such a way that bone that grows or is otherwise seeded into scaffold 200 grows in a way that mimics the variable density of the portions of the native bone being replaced by APC implant 100, as described in greater detail below.


It is possible to map the density of bone, including bone that is to be removed and bone adjacent the bone to be removed. Such a density map can be created by any suitable imaging means. For example, the portion of bone that will be replaced may be scanned and computed tomography used to determine a density profile of the bone. Such a density profile may be created, for example, by analyzing pixel brightness of portions of the scanned bone. It should be understood that other methods, including other imaging modalities, may provide suitable means to create a density map of the bone to be replaced. It should also be understood that it may be desirable to create density maps or profiles of surrounding bone, particularly if the bone being replaced is damaged or otherwise has an abnormal density profile which should not be replicated in APC implant 100.



FIG. 4A is a schematic illustration of a scaffold 200 of APC implant 100 intended for replacement of a medial tibia condyle 22. It should be understood that although scaffold 200 is illustrated as being rectangular, the actual shape of the scaffold 200 may be dictated by the requirements of the particular anatomy at issue. In the example of scaffold 200, the left side of scaffold 200 as shown in FIG. 4A is intended for placement adjacent the resected center of tibia 20, the bottom of scaffold 200 is intended for placement adjacent the resected bottom surface of medial tibia condyle 22, with the top, front, rear, and right sides of scaffold 200 forming defining the exterior faces of scaffold 200. As noted above, a bone density profile of tibia 20 would illustrate that the outer cortical rim has a relatively high the cartilage adapted to replace at least a portion of a joint surface of the joint density, with the density decreasing toward the center of tibia 20. It should also be understood that certain properties, structural features or voids may be provided in scaffold 200, whether or not each are provided by the imaging and/or modeling of natural anatomy described above. For example, the matrix of scaffold 200 is preferably designed to promote vascularization, such as through the inclusion of continuous channels throughout scaffold 200. Further, certain portions of scaffold 200 may have properties different from surrounding portions of the scaffold 200 to provide for particular functionality. For example, the matrix of scaffold 200 may be rougher, have increased texture, and be more vascular to provide for an enhanced ligament attachment site. This may correspond to natural features, such as bone fibers (or Sharpey's fibers) which may provide for attachment sites to bone. Using data corresponding to the bone density profile of tibia 20, scaffold 200 may be created, for example by 3D printing of titanium, so that the scaffold 200 has porosity that generally corresponds to the density profile of the bone being replaced (or, in the case the bone being replaced has an undesirable density profile, for example due to degeneration, the porosity profile of the scaffold would correspond to a desired density profile). It should be understood that other types of metals, as well as non-metals, including bioabsorbable materials or collagen, may individually or in combination form the scaffold 200. At least some inclusion of collagen in scaffold 200 may be preferable to help promote bone growth in and on the scaffold.



FIG. 4B shows a cross section of scaffold 200 taken along a longitudinal plane passing through the center of scaffold 200, as represented by line 4B-4B of FIG. 4A. As shown in FIG. 4B, scaffold 200 may include a variety of porosity zones 210, 220, 230 that generally correspond to the desired density profile of APC implant 100. In the illustrated example, porosity zone 210 may have relatively low porosity corresponding to relatively high density of cortical bone. Porosity zone 230 may have relatively high porosity corresponding to relatively low density of cancellous bone, with porosity zone 220 being intermediate. The amount of porosity may be determined, for example, by the amount of spacing between the metal, which may take a foam or lattice type of configuration. It should be understood that scaffold 200 need not include discrete porosity zones, but rather may include a gradient of porosities that correspond to the desired bone density of APC implant 100. Further, it should be understood that the shape of any porosity zones need not be rectangular or any other rigid shape, but may be dictated by the corresponding shapes of the desired bone density profile.


As shown in FIG. 5, stem cells 300 may be introduced or seeded into and/or onto scaffold 300. The harvesting and seeding of cells may be done by any suitable means, some of which are described in greater detail in U.S. Pat. No. 7,299,805, the contents of which are hereby incorporated by reference herein. For example, the cells used may be any suitable type of viable cells, preferably those that correspond to the native tissue being replaced. This may include, for example, chondrocytes (and/or chondroblasts), osteoblasts, fibrobalsts, and/or pluripotent cells or stem cells. Stem cells may be harvested, for example, from bone marrow or fetal cells. Although cells 300 are generally referred to as stem cells herein, it should be understood that any suitable type of cell or combination of cell types may be alternately used. Upon introduction into scaffold 200, stem cells 300 migrate through the scaffold 200, attaching to the metal that provides the structure of scaffold 200, with the stem cells 300 differentiating into bone cells over time. The attachment may be affected and controlled, for example, by the texture of the surface of scaffold 200 and the size of the pores within the scaffold 200. The use of collagen, as well as adding calcium and controlling the pH balance of the scaffold system may help promote bone growth. The differentiation into the desired cell type or types may be controlled, for example, by applying or exposing the cells to certain environmental conditions such as mechanical forces (static or dynamic), chemical stimuli (e.g. pH), and/or electromagnetic stimuli.


With the stem cells seeded into scaffold 200, the scaffold 200 may be placed inside an incubator. The incubator may include a nutrient rich medium that is flowed through the scaffold 200 to provide a desirable environment for the cells in the scaffold. The bone cells may grow and migrate through scaffold 200, with the bone growing more densely in the zones with low scaffold porosity, such as porosity zone 210, and less densely in the zones with high scaffold porosity, such as porosity zone 230, as shown in FIG. 6.


After the seeded bone cells have migrated and grown into scaffold 200, one or more layers of cartilage 240, 250 may then be grown on top of the bone. For example, a first deep layer 240 of cartilage may be grown on top of the relatively dense bone in porosity zone 210, and a gliding layer 250 may be grown on top of the deep layer 240. Gliding layer 250 may provide a surface for articulation with a bone of a corresponding joint, such as a femoral condyle. The growth of the cartilage layers 240, 250 may also be assisted with the use of an incubator, with the cartilage growth taking place over a period of up to eight weeks, for example. The differentiation between cartilage layers 240, 250 may be based, at least in part, on difference within the scaffold 200 upon which the cartilage grows. Although the cells are described as being seeded and incubated prior to implant, it should be understood that the scaffold 200 may first be implanted into the patient with the cells being seeded into the scaffold 200 intraoperatively.


The implant 100 with both bone grown throughout the scaffold 200 and cartilage layers 240, 250 grown on top of the bone is shown in FIG. 7. At this point, the implant 100 may be ready or near-ready for implantation. For example, in a unicondylar knee replacement procedure, implant 100 may be provided in the operating room where the knee replacement is to take place. Preferably, the medial tibial condyle 22 is resected according to an operative plan with the use of an autonomous or semi-autonomous robotic system, such as the robotic system described in greater detail in U.S. Pat. No. 8,287,522, the disclosure of which is hereby incorporated by reference herein. For example, as shown in FIG. 8A, a robotic device 400 with a robotic arm 410 and a cutting tool end effector 420 may resect medial tibial condyle 22 according to a plan in a computer controlling robotic device 400. Based on the particular geometry of the resected native bone, robotic device 400 may be used to shape implant 100 to have a corresponding fit to the implant site. Implant 100 may be fixed to a stand 430 or other device to secure the implant 100 as the end effector 420 of robotic device 400 customizes the shape of implant 100.


Once shaped, implant 100 may be press-fit, packed, or otherwise implanted into the implant site. The robotic device 400 may also assist in the step of positioning the implant 100 onto the native bone, for example with the aid of a navigation system and/or sensors to position the implant 100 in the desired three-dimensional position with respect to the tibia 20. Any known type of external hardware, such as fixation screws or pegs, may be used to facilitate the initial connection of the implant 100 to the native anatomy. As noted previously, scaffold 200 preferably includes a density profile that mimics or otherwise corresponds to the bone density profile of the native bone that will be positioned adjacent the implant 100. The native bone will grow into the scaffold 200, with the matching density profiles resulting in better bone ingrowth compared to other implants. For example, it has been found that, for fresh allograft and frozen osteochondral graft, it is difficult to get native bone to grow into the implant surface. However, bone consistently grows to surface of metallic porous scaffold 200, particularly with its three-dimensional surface. Furthermore, matching density profiles between the native bone and the scaffold 200 further encourages bony ingrowth into the scaffold 200.


It should be understood that the fabrication of scaffold 200 may be complicated. One alternative option in creating the scaffold is through use of the body's own scaffold as a guide. For example, a user may start with a body portion (e.g. a tibia portion of a knee joint) and repeatedly apply aldehyde to remove tissue, bone, hydroxyapatite, and/or selenium material, leaving only collagen and the scaffold behind. The three-dimensional structure and geometry of the remaining cartilage and scaffold can then be mapped. For example, lasers or other suitable devices may scan or otherwise map the scaffold and cartilage and to store the structure in computer memory so that the structure could be easily reproduced, for example via additive manufacturing. Rather than mapping, a negative mold of the scaffold could be created so that the scaffold could be reproduced with the mold. The scaffold could be created from metal as described above, or alternately created directly with tissue. For example, a 3D printer could be used to build a scaffold directly with bone cells and/or collagen without the need to impregnate a metal scaffold with cells. In other embodiments, the scaffold 200 may be produced in a manner described in U.S. Pat. No. 8,992,703, the disclosure of which is hereby incorporated by reference herein. For example, the method of forming the three-dimensional scaffold 200 may include building the shape by laser melting powdered titanium and titanium alloys, stainless steel, cobalt chrome alloys, tantalum or niobium using a continuous or pulsed laser beam. Individual layers of metal may be scanned using a laser. The laser may be a continuous wave or pulsed laser beam. Each layer or portion of a layer may be scanned to create a portion of a plurality of predetermined unit cells. Successive layers may be deposited onto previous layers and also may be scanned. The scanning and depositing of successive layers may continue the building process of the predetermined unit cells. Continuing the building process may refer not only to a continuation of a unit cell from a previous layer but also a beginning of a new unit cell as well as the completion of a unit cell.


Although described above in the context of replacing a joint, and particularly a tibial condyle of a knee joint, the concepts provided above may extend to creating other alloprosthetic composite prostheses. For example, prostheses with scaffolds similar to those described above, with or without cartilage, may be implemented to replace segmental defects of bone after trauma, for arthrodesis, or for correcting leg length discrepancies. Other potential uses include for spinal fusion, in which the scaffold facilitates the fusion rather than a more typical prosthetic cage device. When used in the spine, the prosthesis may facilitate soft tissue graft, for example to replace the annulus fibrosus and nucleus pulposus with ingrowth into the vertebral endplates. The scaffolds described above could also be used for pure tissue grafts, for example when a rotator cuff is missing. Such an implant could be formed from a tissue scaffold, rather than a metal or bone scaffold, with tissue ingrowth into the tissue scaffold.


Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Claims
  • 1. A method of implanting an alloprosthetic composite implant including an implant scaffold, the method comprising: determining a bone density profile of a bone of a patient to be contacted by the scaffold;forming the scaffold to have a pore density profile, wherein the pore density profile of the scaffold is formed based on the determined bone density profile of the bone of the patient;seeding a plurality of viable cells into the scaffold;incubating the scaffold including the plurality of viable cells to grow bone throughout the scaffold;after growing the bone throughout the scaffold, growing at least one layer of cartilage on top of the grown bone to produce the alloprosthetic composite implant having a first shape;robotically resecting native bone of a patient to have a particular geometry; andafter growing the at least one layer of cartilage on top of the grown bone, fixing the alloprosthetic composite implant having the first shape to a stand, and intraoperatively robotically machining the alloprosthetic composite implant from the first shape into a second shape corresponding to the particular geometry while the alloprosthetic composite implant is fixed to the stand, the second shape being different than the first shape; andimplanting the alloprosthetic composite implant having the second shape into patient adjacent the resected native bone of the patient,wherein a portion of the scaffold intended to contact the native bone is formed with a pore density profile based on the determined bone density profile of the bone of the patient to be contacted by the scaffold.
  • 2. The method of claim 1, wherein the step of forming the scaffold is performed by additive manufacturing.
  • 3. The method of claim 2, wherein the additive manufacturing is 3-D printing.
  • 4. The method of claim 1, wherein the step of robotically resecting native bone of the patient includes forming a first interlocking shape in the native bone and the step of robotically machining the alloprosthetic composite implant includes forming a second interlocking shape in the alloprosthetic composite implant having a complementary shape to the first interlocking shape.
  • 5. The method of claim 1, wherein the formed scaffold includes an inner portion adapted to contact native bone of the patient, and an outer portion opposite the inner portion, a scaffold density of the outer portion being greater than a scaffold density of the inner portion.
  • 6. The method of claim 5, wherein the outer portion of the scaffold is formed with a lower pore density than the inner portion of the scaffold.
  • 7. The method of claim 6, wherein the pore density of the outer portion of the scaffold is based on a density of a cortical section of the bone of the patient.
  • 8. The method of claim 6, wherein the pore density of the inner portion of the scaffold is based on a density of a cancellous section of the bone of the patient.
  • 9. The method of claim 1, wherein the scaffold is formed from metal.
  • 10. The method of claim 9, wherein the metal is titanium.
  • 11. The method of claim 1, wherein the scaffold is formed of a bioabsorbable material.
  • 12. The method of claim 1, wherein seeding the plurality of viable cells into the scaffold includes seeding osteoblasts into the scaffold.
  • 13. The method of claim 1, wherein seeding the plurality of viable cells into the scaffold includes seeding pluripotent cells into the scaffold.
  • 14. The method of claim 1, wherein growing the at least one layer of cartilage on top of the grown bone includes forming a first inner layer of cartilage on the scaffold prior to robotically machining the alloprosthetic composite implant.
  • 15. The method of claim 14, further wherein growing the at least one layer of cartilage on top of the grown bone includes forming a second layer of cartilage on the first layer of cartilage prior to robotically machining the alloprosthetic composite implant.
  • 16. The method of claim 1, wherein incubating the scaffold includes incubating the scaffold in a nutrient rich medium.
  • 17. The method of claim 1, wherein the scaffold is formed of collagen.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 62/359,809 filed Jul. 8, 2016, the disclosure of which is hereby incorporated by reference herein.

US Referenced Citations (256)
Number Name Date Kind
4192021 Deibig et al. Mar 1980 A
4608199 Caplan et al. Aug 1986 A
4609551 Caplan et al. Sep 1986 A
4663720 Duret et al. May 1987 A
4742464 Duret et al. May 1988 A
4936862 Walker et al. Jun 1990 A
5150304 Berchem et al. Sep 1992 A
5197985 Caplan et al. Mar 1993 A
5226914 Caplan et al. Jul 1993 A
5257203 Riley et al. Oct 1993 A
5273964 Lemons Dec 1993 A
5274565 Reuben Dec 1993 A
5365996 Crook Nov 1994 A
5448489 Reuben Sep 1995 A
5452407 Crook Sep 1995 A
5486359 Caplan et al. Jan 1996 A
5514137 Coutts May 1996 A
5556429 Felt Sep 1996 A
5607469 Frey Mar 1997 A
5755809 Cohen et al. May 1998 A
5824084 Muschler Oct 1998 A
5880964 Schall et al. Mar 1999 A
5902825 Jia May 1999 A
6049026 Muschler Apr 2000 A
6112109 D'Urso Aug 2000 A
6140452 Felt et al. Oct 2000 A
6177151 Chrisey et al. Jan 2001 B1
6235043 Reiley et al. May 2001 B1
6241734 Scribner et al. Jun 2001 B1
6248110 Reiley et al. Jun 2001 B1
6254639 Peckitt Jul 2001 B1
6280474 Cassidy et al. Aug 2001 B1
6306177 Felt et al. Oct 2001 B1
6319712 Meenen et al. Nov 2001 B1
6395007 Bhatnagar et al. May 2002 B1
6527810 Johnson et al. Mar 2003 B2
6564083 Stevens May 2003 B2
6572572 Pomatto et al. Jun 2003 B2
6607561 Brannon Aug 2003 B2
6613054 Scribner et al. Sep 2003 B2
6632247 Boyer, II et al. Oct 2003 B2
6696073 Boyce et al. Feb 2004 B2
6711432 Krause et al. Mar 2004 B1
6719761 Reiley et al. Apr 2004 B1
6723131 Muschler Apr 2004 B2
6733747 Anderson et al. May 2004 B2
6736799 Erbe et al. May 2004 B1
6746451 Middleton et al. Jun 2004 B2
6767354 Johanson et al. Jul 2004 B2
6767369 Boyer, II et al. Jul 2004 B2
6776800 Boyer, II et al. Aug 2004 B2
6786930 Biscup Sep 2004 B2
6818018 Sawhney Nov 2004 B1
6827720 Leali Dec 2004 B2
6863899 Koblish et al. Mar 2005 B2
6864101 Winkler et al. Mar 2005 B1
6887246 Bhatnagar et al. May 2005 B2
6932610 Ono et al. Aug 2005 B2
6981948 Pellegrino et al. Jan 2006 B2
6986788 Paul et al. Jan 2006 B2
7018382 Merboth et al. Mar 2006 B2
7045125 Erbe et al. May 2006 B2
7050877 Iseki et al. May 2006 B2
7052517 Murphy et al. May 2006 B2
7063726 Crouch et al. Jun 2006 B2
7087087 Boyer, II et al. Aug 2006 B2
7131605 McPherson et al. Nov 2006 B2
7147846 Anderson et al. Dec 2006 B2
7153307 Scribner et al. Dec 2006 B2
7166570 Hunter et al. Jan 2007 B2
7175336 Voellmicke et al. Feb 2007 B2
7261720 Stevens et al. Aug 2007 B2
7291450 Sowemimo-Coker et al. Nov 2007 B2
7299805 Bonutti Nov 2007 B2
7300465 Paul et al. Nov 2007 B2
7374678 Leach et al. May 2008 B2
7383094 Kopelman et al. Jun 2008 B2
7425549 Little et al. Sep 2008 B2
7442195 Behrens Oct 2008 B1
7447556 McBagonluri et al. Nov 2008 B2
7462181 Kraft et al. Dec 2008 B2
7470371 Dorian et al. Dec 2008 B2
7483558 Greene, Jr. et al. Jan 2009 B2
7621963 Simon et al. Nov 2009 B2
7655010 Serhan et al. Feb 2010 B2
7670384 Kumar et al. Mar 2010 B2
7708742 Scribner et al. May 2010 B2
7736366 Abdelgany et al. Jun 2010 B2
7744597 Gaskins et al. Jun 2010 B2
7747305 Dean et al. Jun 2010 B2
7771431 Scribner et al. Aug 2010 B2
7771590 Leach et al. Aug 2010 B2
7776594 Bays et al. Aug 2010 B2
7780860 Higgins et al. Aug 2010 B2
7806276 Leach et al. Oct 2010 B2
7811290 Rabiner Oct 2010 B2
7819888 Johanson et al. Oct 2010 B2
7831292 Quaid et al. Nov 2010 B2
7832566 Leach et al. Nov 2010 B2
7837884 Dorian et al. Nov 2010 B2
7845499 Higgins et al. Dec 2010 B2
7858296 Sowemimo-Coker et al. Dec 2010 B2
7887598 Evans et al. Feb 2011 B2
7892291 Evans et al. Feb 2011 B2
7914689 Higgins et al. Mar 2011 B2
7923203 Sowemimo-Coker et al. Apr 2011 B2
7992725 Leach et al. Aug 2011 B2
7993578 Kadiyala Aug 2011 B2
7996099 Kopelman et al. Aug 2011 B2
8002733 Kraft et al. Aug 2011 B2
8034014 Higgins et al. Oct 2011 B2
8043253 Kraft et al. Oct 2011 B2
8043377 Guyer et al. Oct 2011 B2
8048297 Leach et al. Nov 2011 B2
8048320 Leach et al. Nov 2011 B2
8048321 Leach et al. Nov 2011 B2
8060236 Hilliard Nov 2011 B2
8062364 Sharkey et al. Nov 2011 B1
8062372 Tsuang et al. Nov 2011 B2
8062534 Higgins et al. Nov 2011 B2
8086336 Christensen Dec 2011 B2
8109919 Kraft et al. Feb 2012 B2
8116900 Slemker et al. Feb 2012 B2
8119013 Leach et al. Feb 2012 B2
8137408 Kadiyala et al. Mar 2012 B2
8147500 Beyar et al. Apr 2012 B2
8152813 Osorio et al. Apr 2012 B2
8160345 Pavlovskaia et al. Apr 2012 B2
8163032 Evans et al. Apr 2012 B2
8163184 Leach et al. Apr 2012 B2
8168692 Wenz May 2012 B2
8183042 Liao et al. May 2012 B2
8187477 Dorian et al. May 2012 B2
8187556 Kadiyala May 2012 B2
8200355 Lee et al. Jun 2012 B2
8221430 Park et al. Jul 2012 B2
8236258 Leach et al. Aug 2012 B2
8287522 Moses et al. Oct 2012 B2
8287915 Clineff et al. Oct 2012 B2
8303967 Clineff et al. Nov 2012 B2
8303976 Sapieszko et al. Nov 2012 B2
8308340 Ferrante et al. Nov 2012 B2
8313742 Kadiyala et al. Nov 2012 B2
8313954 Leach et al. Nov 2012 B2
8328024 Leach et al. Dec 2012 B2
8337711 Dorian et al. Dec 2012 B2
8419802 Evans et al. Apr 2013 B2
8425619 Evans et al. Apr 2013 B2
8435306 Evans et al. May 2013 B2
8455254 Tsai et al. Jun 2013 B2
8460686 Clineff et al. Jun 2013 B2
8483863 Knox Jul 2013 B1
8497236 Benedict et al. Jul 2013 B2
8512575 Leach et al. Aug 2013 B2
8551178 Sharkey et al. Oct 2013 B2
8567609 Landrigan et al. Oct 2013 B2
8591391 Chavarria et al. Nov 2013 B2
8596470 Leach et al. Dec 2013 B2
8603346 Leach et al. Dec 2013 B2
8613938 Akella et al. Dec 2013 B2
8617171 Park et al. Dec 2013 B2
8623094 Evans et al. Jan 2014 B2
8652148 Zuhars Feb 2014 B2
8657482 Malackowski et al. Feb 2014 B2
8663146 Higgins et al. Mar 2014 B2
8685429 Koblish et al. Apr 2014 B2
8690874 Thorne Apr 2014 B2
8702809 Nauman et al. Apr 2014 B2
8715353 Bagga et al. May 2014 B2
8734822 Koblish et al. May 2014 B2
8742072 Thorne Jun 2014 B2
8783470 Hecker et al. Jul 2014 B2
8801586 Dorian et al. Aug 2014 B2
8808551 Leach et al. Aug 2014 B2
8838263 Sivak et al. Sep 2014 B2
8845736 Zhang et al. Sep 2014 B2
8876911 Murphy et al. Nov 2014 B2
8882848 Sharkey et al. Nov 2014 B2
8950586 Dorian et al. Feb 2015 B2
8992703 O'Neill et al. Mar 2015 B2
8992862 Leach et al. Mar 2015 B2
8998998 Sharkey et al. Apr 2015 B2
9011800 Leach et al. Apr 2015 B2
9039998 Guillemot et al. May 2015 B2
9045735 Muschler et al. Jun 2015 B2
9056017 Kotlus Jun 2015 B2
20010033857 Vyakarnam Oct 2001 A1
20020007294 Bradbury Jan 2002 A1
20020029045 Bonutti Mar 2002 A1
20020183417 Shimp Dec 2002 A1
20030039676 Boyce et al. Feb 2003 A1
20030055316 Brannon Mar 2003 A1
20030055431 Brannon Mar 2003 A1
20030109784 Loh et al. Jun 2003 A1
20030114936 Sherwood et al. Jun 2003 A1
20030135214 Fetto et al. Jul 2003 A1
20030138473 Koblish et al. Jul 2003 A1
20030157271 Duignan et al. Aug 2003 A1
20030216669 Lang et al. Nov 2003 A1
20030236573 Evans et al. Dec 2003 A1
20040022689 Wulf et al. Feb 2004 A1
20050049706 Brodke et al. Mar 2005 A1
20050101673 Norden et al. May 2005 A1
20050119219 Bellini et al. Jun 2005 A1
20050251266 Maspero et al. Nov 2005 A1
20050261795 Ghosh et al. Nov 2005 A1
20050272153 Xuenong et al. Dec 2005 A1
20060057184 Nycz et al. Mar 2006 A1
20060064164 Thelen et al. Mar 2006 A1
20060105015 Perla et al. May 2006 A1
20060172934 Nycz et al. Aug 2006 A1
20060282020 Bertagnoli et al. Dec 2006 A1
20070010440 Schense et al. Jan 2007 A1
20070113951 Huang May 2007 A1
20070123894 Claypool et al. May 2007 A1
20070244484 Luginbuehl Oct 2007 A1
20070259018 McKay Nov 2007 A1
20070264612 Mount Nov 2007 A1
20070265705 Gaissmaier et al. Nov 2007 A1
20070275028 Barry et al. Nov 2007 A1
20070276501 Betz et al. Nov 2007 A1
20070287988 Trebing et al. Dec 2007 A1
20080031915 Becerra Ratia et al. Feb 2008 A1
20080038487 Barron et al. Feb 2008 A1
20080113008 Roche May 2008 A1
20080249632 Stone et al. Oct 2008 A1
20080294085 Stamps et al. Nov 2008 A1
20080294269 Fell Nov 2008 A1
20090005868 Gundlapalli et al. Jan 2009 A1
20090081076 Baege et al. Mar 2009 A1
20090081169 Egrise et al. Mar 2009 A1
20090123378 Wong et al. May 2009 A1
20090164014 Liljensten et al. Jun 2009 A1
20090287332 Adusumilli et al. Nov 2009 A1
20090292379 Pitz Nov 2009 A1
20100076503 Beyar et al. Mar 2010 A1
20100114351 Kopelman et al. May 2010 A1
20100145451 Dee Jun 2010 A1
20100152873 Dunne et al. Jun 2010 A1
20100179549 Keller et al. Jul 2010 A1
20100256692 Kang et al. Oct 2010 A1
20100268363 Karim et al. Oct 2010 A1
20110106093 Romano et al. May 2011 A1
20110172611 Yoo et al. Jul 2011 A1
20130060278 Bozung et al. Mar 2013 A1
20130144392 Hughes Jun 2013 A1
20130204384 Hensley Aug 2013 A1
20130224278 Czaja Aug 2013 A1
20130267026 Bonutti Oct 2013 A1
20130325142 Hunter Dec 2013 A1
20140012393 Shin et al. Jan 2014 A1
20140263214 Dahotre et al. Sep 2014 A1
20140336545 Bonuttti Nov 2014 A1
20140371897 Lin et al. Dec 2014 A1
20150182295 Bozung et al. Jul 2015 A1
20170172743 Bonutti Jun 2017 A1
Foreign Referenced Citations (15)
Number Date Country
1689330 Aug 2006 EP
6149950 Mar 1986 JP
2003126124 May 2003 JP
2004159982 Jun 2004 JP
20060108961 Oct 2006 KR
20080103389 Nov 2008 KR
0185040 Nov 2001 WO
03056320 Jul 2003 WO
2005107949 Nov 2005 WO
2006026981 Mar 2006 WO
2007025290 Mar 2007 WO
2007139949 Dec 2007 WO
2008143469 Nov 2008 WO
2010102059 Sep 2010 WO
2014145406 Sep 2014 WO
Non-Patent Literature Citations (4)
Entry
Extended European Search Report for EP17180110 dated Mar. 26, 2018.
Partial European Search Report for EP 17 18 0110 completed Nov. 20, 2017.
Extended European Search Report for Application No. EP 19192955.3 dated Jan. 31, 2020, 5 pages.
European Search Report for Application No. EP 19192955.3, dated Mar. 11, 2021, 7 pages.
Related Publications (1)
Number Date Country
20180008418 A1 Jan 2018 US
Provisional Applications (1)
Number Date Country
62359809 Jul 2016 US